NYSE · NOVTU
Technology · Hardware, Equipment & Parts
$57.43
Down-$0.37 (-0.64%)
Updated Sep 19, 2026, 6:36 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
NOVTU closed at $57.43 after 19 trading sessions, down 7.76% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $57.44 | $57.44 | $56.695 | $57.43 | 4.35K |
| Sep 17, 2026 | $57.80 | $58.03 | $57.80 | $58.03 | 611 |
| Sep 16, 2026 | $59.16 | $59.16 | $56.57 | $57.03 | 9.05K |
| Sep 15, 2026 | $59.36 | $59.52 | $58.95 | $58.95 | 3.66K |
| Sep 14, 2026 | $66.96 | $66.96 | $59.74 | $59.86 | 7.44K |
| Sep 11, 2026 | $62.58 | $62.58 | $61.64 | $61.64 | 1.63K |
| Sep 10, 2026 | $60.78 | $61.15 | $60.77 | $61.08 | 1.42K |
| Sep 9, 2026 | $62.21 | $62.40 | $61.89 | $61.89 | 3.27K |
| Sep 8, 2026 | $63.40 | $64.29 | $63.38 | $63.59 | 2.46K |
| Sep 4, 2026 | $63.13 | $63.13 | $62.65 | $62.68 | 744.16 |
| Sep 3, 2026 | $62.32 | $62.32 | $61.62 | $61.62 | 837 |
| Sep 2, 2026 | $61.56 | $61.69 | $61.05 | $61.18 | 3.27K |
| Sep 1, 2026 | $60.73 | $61.04 | $60.59 | $60.92 | 9.44K |
| Aug 31, 2026 | $60.36 | $62.33 | $60.36 | $62.25 | 11.63K |
| Aug 27, 2026 | $60.85 | $61.64 | $60.83 | $61.64 | 2.32K |
| Aug 26, 2026 | $60.35 | $61.53 | $60.35 | $61.52 | 879 |
| Aug 25, 2026 | $60.00 | $60.00 | $59.83 | $59.91 | 1.89K |
| Aug 24, 2026 | $60.76 | $60.76 | $59.66 | $59.66 | 5.7K |
| Aug 21, 2026 | $61.90 | $62.26 | $61.37 | $62.26 | 1.73K |
The latest Smart Investors Daily articles mentioning NOVTU.
NOVTU research
Company profile and research snapshot.
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 13, 2026 | Baird | Outperform | — |
| Mar 30, 2026 | Baird | Outperform | — |
| Aug 11, 2025 | Baird | Neutral | — |
| Mar 3, 2025 | Baird | Neutral | — |
| Nov 6, 2024 | Baird | Neutral | — |
No generated briefing is available yet.
Yahoo · Sep 4, 2026
On August 5, Novanta Inc. (NASDAQ:NOVT) reported second quarter results showing something rarer than strong revenue growth: profit growth that beat it by a wide margin. Revenue rose 10.3% year over year to $265.8 million, but net income nearly tripled and cash from operations quadrupled. That kind of gap between the top and bottom line […]
Yahoo · Sep 3, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
ChartMill · Sep 1, 2026
Discover why Novanta (NOVTU) passes the Caviar Cruise quality screen: strong EBIT growth, 25.5% ROIC, and solid cash conversion.
Yahoo · Aug 28, 2026
BOSTON, August 28, 2026--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NOVTU.
